Dyskinesia

The original approval for chorea associated with Huntington disease was based on the phase 3 KINECT-HD study, an 128-patient cohort trial in which valbenazine met its primary end point.

On average, clinician-rated TD severity, measured by AIMS, and patient-reported assessment of the physical, social and emotional impact of TD, measured by TDIS, decreased with one-capsule, once-daily valbenazine over 48 weeks.

Teva’s VMAT2 inhibitor was previously approved in a twice-daily formulation. The once-daily extended-release treatment, marketed as Austedo XR, is expected to be available later in 2023 in doses of 6 mg, 12 mg, and 24 mg.

At weeks 54, 106, and 145, most of both age groups achieved treatment success on both the CGIC and PGIC, with numerically higher percentages observed in younger vs older participants.

Tardive dyskinesia can present many challenges in its treatment and can be difficult to differentiate from similar disorders.

The chief medical officer of Neurocrine Biosciences spoke about how long-term data on valbenazine (Ingrezza) has helped shape the understanding of the effect tardive dyskinesia can have on patients, and how it can inform better utilization of the medication.